{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:27:01Z","timestamp":1761989221058,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40264-018-0717-4","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T23:49:08Z","timestamp":1534895348000},"page":"999-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ibuprofen and Paracetamol: Acceptably Safe for All?"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-306X","authenticated-orcid":false,"given":"Filippo","family":"Pigazzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isla","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"21","key":"717_CR1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, VIGOR Study Group, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520\u20138.","journal-title":"N Engl J Med"},{"key":"717_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0686-7","author":"M Duong","year":"2018","unstructured":"Duong M, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N. Coronary events after dispensing of ibuprofen: a propensity score-matched cohort study versus paracetamol in the French nationwide claims database sample. Drug Saf. 2018. \n                    https:\/\/doi.org\/10.1007\/s40264-018-0686-7\n                    \n                   (epub).","journal-title":"Drug Saf."},{"issue":"9357","key":"717_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","volume":"361","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361(9357):573\u20134.","journal-title":"Lancet"},{"issue":"9","key":"717_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.52.9.1265","volume":"52","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003;52(9):1265\u201370.","journal-title":"Gut"},{"issue":"26","key":"717_CR5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH, L\u00fcscher TF, Libby P, Husni ME, et al. PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"23","key":"717_CR6","first-page":"1843","volume":"38","author":"TM MacDonald","year":"2017","unstructured":"MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the standard care vs. celecoxib outcome trial (SCOT). Eur Heart J. 2017;38(23):1843\u201350.","journal-title":"Eur Heart J"},{"key":"717_CR7","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","volume":"357","author":"M Bally","year":"2017","unstructured":"Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.","journal-title":"BMJ"},{"issue":"18","key":"717_CR8","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.110.956490","volume":"122","author":"I Sudano","year":"2010","unstructured":"Sudano I, Flammer AJ, P\u00e9riat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122(18):1789\u201396.","journal-title":"Circulation"},{"issue":"6","key":"717_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/bcp.12032","volume":"75","author":"EJ Turtle","year":"2013","unstructured":"Turtle EJ, Dear JW, Webb DJ. A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. Br J Clin Pharmacol. 2013;75(6):1396\u2013405.","journal-title":"Br J Clin Pharmacol"},{"issue":"7490","key":"717_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/bmj.330.7490.539-b","volume":"330","author":"N Moore","year":"2005","unstructured":"Moore N. Assessing drug safety. BMJ. 2005;330(7490):539\u201340.","journal-title":"BMJ"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-0717-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0717-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0717-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T19:40:21Z","timestamp":1566416421000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-0717-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0717-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"22 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this commentary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas M. Macdonald was a principal investigator of the SCOT trial. Filippo Pigazzani, Isla Mackenzie, and Thomas M. MacDonald have no other conflicts of interest that are directly relevant to the content of this commentary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}